Tuesday, August 27, 2019 1:05:35 PM
On a related point that I've brought up before: what Diwan can or can't produce in his Theracour lab is s big red herring. These rumors by "inside sources" are a part of it.
It's a distraction from the question: why didn't NNVC pay a professional contract CMC chemistry lab, that typically has a few centuries of specialized process design and scale-up chemistry experience distributed among its staff, to design and scale up the process for them?
It's completely predictable that Diwan, who has zero experience in such matters, wouldn't be able to lead a team over 14 years to accomplish what a competent group of chemists who specialize in solving these exact problems could do in few weeks.
The answer, in my opinion, is this has always been strong evidence that Diwan's only interest was having an excuse for NNVC to pay Theracour as much of that $92M as possible in salaries and R&D costs.
It's a distraction from the question: why didn't NNVC pay a professional contract CMC chemistry lab, that typically has a few centuries of specialized process design and scale-up chemistry experience distributed among its staff, to design and scale up the process for them?
It's completely predictable that Diwan, who has zero experience in such matters, wouldn't be able to lead a team over 14 years to accomplish what a competent group of chemists who specialize in solving these exact problems could do in few weeks.
The answer, in my opinion, is this has always been strong evidence that Diwan's only interest was having an excuse for NNVC to pay Theracour as much of that $92M as possible in salaries and R&D costs.
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
